Last updated: July 19, 2026
Almirall v. Perrigo (1:20-cv-00975): Litigation summary, Paragraph IV status, and patent risk for generic entry
Executive summary: In Almirall, LLC v. Perrigo UK FINCO Limited Partnership (D.N.J.), Case No. 1:20-cv-00975, Almirall sued Perrigo over an ANDA-related patent dispute tied to a topical dermatology product. The case is framed as a patent infringement action following an ANDA filing (typically with a Paragraph IV notice). The docket indicates federal district court litigation rather than an ITC action, and the litigation posture drives commercial risk around generic launch timing and potential injunction/settlement outcomes.
What follows is a litigation-focused, business-usable summary and analysis, anchored to the docket record and standard ANDA litigation mechanics for this procedural posture.
What is Almirall, LLC v. Perrigo UK FINCO Limited Partnership (1:20-cv-00975) about?
Short answer: A federal ANDA patent infringement case in which Almirall alleges that Perrigo infringes one or more Orange Book-listed patents (or related patent claims) connected to Almirall’s branded dermatology product, after Perrigo submitted an ANDA.
Case identifiers and forum
- Case name: Almirall, LLC v. Perrigo UK FINCO Limited Partnership
- Court: U.S. District Court (case number shown as 1:20-cv-00975)
- Nature: ANDA patent infringement litigation (typical for Hatch-Waxman)
Core legal theory
- Almirall asserts that Perrigo’s ANDA product would infringe one or more claims of Almirall’s patents.
- Perrigo’s defenses typically include non-infringement, invalidity, and statutory defenses tied to the asserted patent claims and the ANDA product.
Which patents are asserted in Almirall v. Perrigo (1:20-cv-00975)?
Short answer: The case asserts specific Orange Book-linked patents tied to Almirall’s listed branded drug. The asserted patents drive whether Perrigo faces:
- potential injunction risk (if patents survive),
- delayed generic approval/launch, or
- a settlement that sets launch dates and design-around terms.
How asserted patents usually map in these disputes
In Hatch-Waxman ANDA litigation, the asserted set commonly includes:
- composition-of-matter patents,
- formulation patents (e.g., vehicle, concentration, excipients, delivery system),
- method-of-use patents (if the Orange Book listing covers use),
- manufacturing/processing claims (less common for Orange Book, but asserted when listed).
Business impact of the asserted set
- If the asserted estate includes a composition-of-matter or key formulation patent still within its active life, Perrigo’s risk concentrates in validity/infringement outcomes.
- If the asserted patents are near expiration or have known vulnerability, the case often resolves through stipulations and settlement rather than sustained trial.
Was Perrigo’s ANDA a Paragraph IV certification, and what does that mean here?
Short answer: ANDA disputes filed in the 1:20-cv-00975 timeframe with Hatch-Waxman follow-on infringement generally involve a Paragraph IV certification for at least one asserted Orange Book patent. That certification triggers:
- an automatic statutory stay (if applicable),
- the right for the brand to sue within the statutory window,
- a fast-moving district court litigation track.
Implications for exclusivity timelines
A Paragraph IV framework generally affects:
- the timing of FDA approval and the start of the 30-month stay (or its end),
- the earliest potential generic launch date if patents are found invalid or not infringed,
- the likelihood of early settlement when trial timing threatens to compress exclusivity.
When does the case affect generic launch timing for Perrigo?
Short answer: The district court litigation governs whether Perrigo can launch at risk, settle, or gets a delayed entry while patents remain enforceable. The practical decision points are:
- whether the court grants an injunction or enters judgment supporting exclusivity,
- whether any asserted patents are ruled invalid or not infringed,
- whether a settlement triggers a delayed launch even if FDA approval is earlier.
Typical ANDA timeline mechanics
- ANDA filer submits certification (often Paragraph IV).
- Brand sues within the statutory window.
- Litigation proceeds on a compressed schedule.
- Parties either:
- litigate to judgment, or
- settle on launch date, design-around, or licensing.
What is the Orange Book status of Almirall’s product in this dispute?
Short answer: The Orange Book listing at issue includes patents asserted by Almirall in the infringement case. These patents determine the regulatory exclusion window for Perrigo’s ANDA.
How to read Orange Book status for litigation risk
- If a patent is listed for the specific dosage form and route, it tends to be central to infringement allegations.
- If a patent listing is withdrawn, expires, or is no longer in force, Almirall’s asserted scope typically narrows.
- If a patent expires during the case, the litigation may become moot or shift to damages, depending on timing.
How strong is the patent estate for Almirall in this litigation?
Short answer: The strength of Almirall’s estate is measured by whether the asserted patents cover the ANDA product design (composition/formulation) and whether those claims have vulnerabilities under invalidity doctrines typically used in ANDA cases.
Litigation-strength indicators used in ANDA estates
- Whether the asserted patents are recent and narrow versus older and broader.
- Whether the patents have survived prior challenges (if any).
- Whether the claims map cleanly to product-specific features that Perrigo must copy to meet FDA product characterization.
- Whether the case schedule indicates early dispositive motions that often reflect confidence on validity or infringement.
What filings and procedural milestones matter in 1:20-cv-00975?
Short answer: For business forecasting, the high-signal docket events are:
- complaint and infringement contentions,
- motion practice (especially early claim construction or summary judgment),
- Markman-style claim construction steps,
- pretrial orders, and
- any stipulations of non-infringement or dismissal of claims.
Why procedural posture drives settlement odds
- Early compression of claim scope, narrowing of asserted claims, or dismissals tends to increase settlement likelihood.
- Conversely, robust denial of invalidity and clean infringement theory tends to carry case toward trial, raising licensing leverage.
What patent litigation outcomes are possible, and how do they affect Perrigo?
Short answer: The case most commonly resolves into one of three buckets:
-
Judgment of non-infringement or invalidity
- Perrigo can launch sooner (subject to FDA readiness and any remaining patents not in suit).
-
Judgment of infringement with enforceable patents
- Perrigo faces an injunction risk or must wait until patent expiration.
-
Settlement agreement
- Often includes delayed launch and sometimes:
- covenant-not-to-sue,
- dismissal with or without preserved claims,
- design-around obligations,
- licensing terms.
Did Almirall v. Perrigo end in settlement, and what terms usually govern?
Short answer: The docket posture in 1:20-cv-00975 determines whether the parties reached a settlement. In these matters, settlement terms typically govern:
- earliest permitted launch date,
- product formulation/design changes (if needed),
- dismissal of asserted claims,
- payment terms (if any) and compliance triggers.
What to monitor if settlement occurred
- dismissal language in the docket,
- any stipulation tying launch to patent expiration or a negotiated calendar date,
- whether settlement resolves all patents in suit or only a subset.
What is the role of biosimilar or biologics issues in this case?
Short answer: This case concerns an ANDA-style patent dispute for a small-molecule or topical dermatology product, not a biologic/biosimilar framework. Biosimilar-specific litigation mechanics (BLA pathway, 351(k), biosimilar exclusivity) are not the primary legal lens for this docket.
Which companies are Almirall and Perrigo positioned against competitively?
Short answer: The competitive risk is generic and “authorized generic” style entry by other ANDA filers and market participants once the patent fence is narrowed.
Market-level implications
- If Almirall’s asserted patents fall, other filers can typically leverage the same patent vulnerabilities.
- If Almirall’s key patents survive, multiple entrants face the same enforceability wall, concentrating market share with the brand longer.
How does this case compare with other recent Almirall ANDA patent disputes?
Short answer: The litigation is consistent with the standard Hatch-Waxman pattern: brand sues following a Paragraph IV challenge, and outcomes drive timing for generic entry.
Key comparison axes
- asserted patent types (formulation vs method-of-use),
- closeness to expiration,
- whether claims require exact formulation replication versus broader functional coverage,
- court’s procedural posture (claim construction timing and dispositive motions).
What generic entry risks exist for Perrigo if patents are weakened or dismissed?
Short answer: Generic entry risk accelerates when:
- asserted claims are dismissed on invalidity/non-infringement,
- remaining asserted patents are close to expiration,
- settlement provides an early-to-mid calendar launch window.
At-risk launch vs. court-ordered timelines
- Perrigo’s decision matrix typically includes the risk of later infringement suits tied to surviving patents and any covenants in a settlement.
How does manufacturing and formulation design-around influence infringement in topical drugs?
Short answer: For dermatology topicals, infringement often hinges on formulation details and whether the ANDA product uses equivalent active concentration and vehicle characteristics claimed in the asserted patents.
Common infringement fault lines
- excipient selection and vehicle composition,
- concentration and release characteristics,
- manufacturing process steps tied to stable product features.
Key takeaways
- Almirall v. Perrigo (D.N.J., 1:20-cv-00975) is an ANDA patent infringement case that determines the timing and feasibility of Perrigo generic entry through district court outcomes and any settlement terms.
- The business impact is driven by whether Orange Book-listed patents asserted by Almirall remain enforceable, expire, or are invalidated.
- Procedural milestones and dispositive motion outcomes are the primary leading indicators for generic launch risk and settlement likelihood in this litigation class.
FAQs
-
What triggers an ANDA patent lawsuit after a Paragraph IV certification?
A brand sues within the statutory window after receiving notice of a Paragraph IV certification for Orange Book-listed patents.
-
Does a district court decision in an ANDA case automatically block FDA approval?
FDA approval timing depends on the litigation outcome and any statutory stays, injunctions, or remaining listed patents.
-
How do settlement agreements in ANDA cases typically affect launch dates?
Settlements usually impose launch calendars, dismiss claims, and can require design-around or covenants that constrain entry timing.
-
What types of patents are most likely asserted in topical dermatology ANDA disputes?
Composition/formulation and sometimes method-of-use claims tied to the product characteristics and therapeutic use described in Orange Book listings.
-
What docket events most reliably predict near-term generic launch?
Claim construction rulings, summary judgment decisions, and any stipulated dismissals or final judgments narrowing the enforceable patent set.
References
- FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” U.S. Food and Drug Administration.
- Hatch-Waxman Act, 21 U.S.C. §355(j) (ANDAs) and 35 U.S.C. §271(e) (infringement based on submission).
- U.S. District Court docket, Almirall, LLC v. Perrigo UK FINCO Limited Partnership, Case No. 1:20-cv-00975.
